Form 4: Teva Exec Daniell Reports 141,478 RSU Grant
Insider Transaction Report
Richard Daniell, Teva's Exec. VP, European Commercial, reported the acquisition of 141,478 restricted share units.
Summary
- Richard Daniell, Executive Vice President, European Commercial for Teva Pharmaceutical Industries Ltd., reported the acquisition of 141,478 restricted share units (RSUs).
- These RSUs were received upon the satisfaction of performance criteria for previously granted performance share units.
- Each RSU represents a contingent right to receive one ordinary share or its cash equivalent at settlement.
- The RSUs are subject to time-based vesting and are scheduled to vest on March 3, 2026.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a moderately positive event, reflecting the retention and incentivization of a key executive through equity compensation tied to performance and future vesting, which is generally seen as a positive for corporate governance and alignment.
Positives
- The grant of 141,478 restricted share units to a key executive indicates continued alignment of management incentives with shareholder interests.
- The satisfaction of performance criteria for previous performance share units suggests the executive met specific targets.
Future Outlook
The filing indicates future vesting of restricted share units on March 3, 2026, contingent on time-based criteria.
Industry Context
StockSavvy.ai notes that executive equity grants, such as restricted share units, are a standard component of compensation packages in the pharmaceutical industry, aiming to incentivize long-term performance and align executive interests with shareholder value creation. This is a routine disclosure for such compensation.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Executive Compensation | Grant of 141,478 restricted share units to Exec. VP, European Commercial, upon satisfaction of performance criteria, subject to time-based vesting. | 01/27/2026 | Aligns executive incentives with long-term company performance and shareholder value. |
Stakeholder Impact
- Shareholders: Potential for increased alignment of executive interests with long-term shareholder value through equity-based compensation.
- Employees: Reflects standard executive compensation practices within the company.
Next Steps
- The restricted share units are scheduled to vest on March 3, 2026, subject to time-based vesting conditions.
Key Dates
| Date | Description |
|---|---|
| 01/27/2026 | Date of earliest transaction (acquisition of restricted share units). |
| 01/29/2026 | Date the Form 4 was signed. |
| 03/03/2026 | Vesting date for the restricted share units. |
Keywords
Teva Pharmaceutical Industries, TEVA, Richard Daniell, Form 4, Restricted Share Units, RSU, Executive Compensation, Insider Transaction, Equity Grant, Performance Share Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.